NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Clinical trials for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED trials appear
Sign up with your email to follow new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Targeting CAR t therapy aims to outperform standard treatment in lymphoma
Disease control Recruiting nowThis study tests a new cell therapy called ronde-cel that targets two proteins (CD19 and CD20) on lymphoma cells, compared to standard CAR T-cell therapy that targets only one. About 400 adults with large B-cell lymphoma that came back or didn't respond to first treatment will ta…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 02:15 UTC
-
New CAR T-Cell therapy targets tough lymphoma cases
Disease control Recruiting nowThis study tests a single dose of a new cell therapy (MB-CART19.1) in 26 adults with a type of blood cancer called non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses the patient's own immune cells, modified to attack cancer cells. Parti…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE2 • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New immune cell therapy takes on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called CD19 t-haNK, which uses specially designed immune cells to target and kill cancer cells. It is for 10 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goal is …
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for hard-to-treat lymphoma? early trial of LTZ-301 begins
Disease control Recruiting nowThis early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo offers hope for patients with stubborn lymphomas
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combina…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE2 • Sponsor: Seda S. Tolu • Aim: Disease control
Last updated May 13, 2026 15:58 UTC